The Cancer Money Trail: From Research to Patents and Licensing
What happens when publicly or charitably supported cancer research produces intellectual property and moves toward commercial development?
Research is not the end of the cancer money trail. Sometimes a discovery becomes an invention. An invention may be protected by intellectual-property law. Rights may then be licensed to another organisation, and that organisation may invest in development, manufacturing and clinical testing.
But there are several points where a research story can be overstated. A grant is not a patent. A patent is not a treatment. A licence is not a market approval. And a commercial deal is not proof that patients benefited. Part 5 follows the chain carefully.
From knowledge to intellectual property
Research can produce many different outputs: publications, datasets, biological materials, software, methods and inventions. Some inventions may qualify for patent protection; others may be kept as know-how, shared as research tools or published without patent protection.
NIH policy states that federally funded research results should be made available to the public and research community, while inventions arising from funded research can be subject to the Bayh-Dole Act and its implementing regulations.
What Bayh-Dole actually does
The Bayh-Dole Act of 1980 created a framework under which many universities, nonprofit institutions and businesses receiving federal research funding can elect to retain rights to qualifying inventions, provided they meet statutory and regulatory obligations.
NIH guidance explains that recipients must report subject inventions to the funding agency. They can elect to retain title, must meet patent-filing requirements when applicable, and must keep the government informed about patenting and efforts to bring the invention into practical use.
The federal government also receives a nonexclusive licence to practise the invention for or on behalf of the United States. In other words, the legal system does not simply hand a federally supported invention to a private company with no continuing government rights.
The commercialisation chain
A simplified documented pathway is:
PUBLIC FUNDING → RESEARCH → INVENTION → DISCLOSURE → PATENT → LICENCE → DEVELOPMENT → CLINICAL TESTING → REGULATORY REVIEW → PATIENT USE
Not every project travels through every stage. Many stop at research. Some inventions are never patented. Some patents are never licensed. Some licences never produce a viable product. Some products fail clinical trials or never obtain regulatory approval.
Why licensing matters
Licensing is the legal mechanism through which an owner can allow another organisation to use protected technology under agreed conditions. Depending on the agreement, consideration can include fees, milestone payments, royalties, equity or other arrangements.
For public research, licensing can be a way of moving a discovery from an institution that is designed primarily to conduct research into a company that has the manufacturing, regulatory and commercial capacity to develop it.
Royalties are not the same as profit
NIH policy addresses income generated from federally supported inventions, including royalties and licensing fees. But a royalty payment received by an institution does not automatically tell us how profitable a final product is, how much a company spent developing it, or how much money flowed back to the original research programme.
This distinction is essential for an evidence-led investigation. We should only report a dollar figure as cancer-specific when the underlying record establishes that it is cancer-specific.
Taxol: a documented cancer example
NCI provides a useful case study in Taxol, the cancer drug based on paclitaxel. Scientists isolated paclitaxel from the Pacific yew tree in the 1960s. NCI later conducted preclinical work and phase 1 and 2 clinical trials.
NCI records that a 1988 Cooperative Research and Development Agreement involved Bristol-Myers Squibb in future production for clinical trials. NCI also records that Bristol-Myers Squibb used semi-synthesis technology licensed from Florida State University to develop a synthetic form of paclitaxel and produce sufficient supplies.
The FDA approved Taxol for ovarian cancer in 1992 and advanced breast cancer in 1994. NCI's account shows how public research, university technology, clinical research and commercial development can intersect in a real cancer product.
What Taxol does — and does not — prove
Taxol is evidence that a publicly supported research pathway can contribute to a commercially developed cancer medicine. It does not prove that every publicly funded discovery becomes profitable, nor does it establish that the public sector alone carried the cost or risk of the final product.
That is exactly why case-by-case tracing matters. The funding history, invention record, licensing agreement, development costs, clinical evidence and regulatory history can all be different.
Who benefits?
The answer can involve several groups: patients, researchers, universities, inventors, companies, investors, health systems and governments. Benefits can be scientific, medical or financial, and they may occur at different times.
For a public funder, the policy objective may be improved health and the practical use of discoveries. For a university, successful licensing can support research and technology transfer. For a company, commercialisation can create revenue if a product succeeds. For patients, the most important outcome is whether an effective intervention becomes available and accessible.
The important unanswered questions
- Which specific grant supported the discovery?
- Who was the recipient institution?
- Was an invention reported?
- Who retained title or other rights?
- Was a patent filed or granted?
- Was the technology licensed?
- What consideration or royalties were specified?
- Who funded later development and trials?
- Did regulators approve the resulting product?
- Did patients actually receive it?
Where the investigation goes next
Parts 1–5 have established the framework: cancer is a collection of diseases; research money comes from multiple sources; funding is geographically concentrated; awards flow into institutions and projects; and some discoveries can move into patents and licensing.
The next stage should go deeper rather than simply becoming longer. Specific patents, licences, companies, clinical trials and financial records can be examined one discovery at a time. That is where the difference between a research grant and a commercial outcome becomes measurable.
Both sides. One record. Evidence before conclusions. Primary sources are prioritised. Facts, estimates and uncertainty are distinguished, and figures are not combined when their definitions, periods or coverage are materially different.
← Read Part 4: Who Receives the Cancer Research Money?